A. Carter

发表

Multiple Source Biosimilar Insulin, What’s a Provider to Do?

A. Carter, 2014, Journal of diabetes science and technology.

A prospective, randomized, multicentered controlled trial to compare the annual glycemic and quality outcomes of patients with diabetes mellitus monitored with weekly fructosamine testing versus usual care.

A. Carter, Cameron C. Lindsey, S. Mangum, 2004, Diabetes technology & therapeutics.

FDA-Approved Biosimilar Insulin

A. Carter, 2014, Journal of diabetes science and technology.

Will Biosimilar Insulins Be Cheaper?

L. Heinemann, A. Carter, 2017, Diabetes technology & therapeutics.

Quality Control of Insulins and Biosimilar Insulins

David C Klonoff, Lutz Heinemann, D. Klonoff, 2016, Journal of diabetes science and technology.

In the Biosimilar Marketplace Will There Be 50 Ways to Leave Your Insulin?

A. Carter, 2016, Journal of diabetes science and technology.

Insulin Storage: A Critical Reappraisal

Lutz Heinemann, Amin Zayani, L. Heinemann, 2020, Journal of diabetes science and technology.

Insulin Concentration in Vials Randomly Purchased in Pharmacies in the United States: Considerable Loss in the Cold Supply Chain

Lutz Heinemann, L. Heinemann, A. Carter, 2018, Journal of diabetes science and technology.

In Response to Letters to the Editor From the American Diabetes Association and Eli Lilly in Regard to: Insulin Concentration in Vials Randomly Purchased in Pharmacies in the United States: Considerable Loss in the Cold Supply Chain

L. Heinemann, A. Carter, 2018, Journal of diabetes science and technology.

An Analysis of the Assessment of Glycated Hemoglobin Using A1cNow+™ Point-of-Care Device Compared to Central Laboratory Testing—an Important Addition to Pharmacist-Managed Diabetes Programs?

A. Carter, 2008, Journal of Diabetes Science and Technology.

Dual test diabetes screening project: screening for poor glycemic control in a large workplace population.

A. Carter, D. Greene, M. Cooney, 2000, Diabetes technology & therapeutics.